Get to know our clinical trials
Randomized, multicenter, crossover study of single-patient imaging and dosimetry testing of lutetium (177Lu) rhPSMA-10.1 and lutetium (177Lu) vipivotide tetraxetane (Pluvicto®) in patients with metastatic prostate cancer in
THIS STUDY IS BEING CONDUCTED TO LEARN MORE ABOUT INJECTABLE RHPSMA-10.1 LUTETIUM (177LU) (THE "STUDY DRUG") IN MEN WITH PROSTATE CANCER THAT HAS PROGRESSED DURING OR AFTER PRIOR TREATMENT.
Specialist
Nuclear Medicine Department
Navarre headquarters
Technical Summary
- RANDOMIZED, MULTICENTER, CROSSOVER STUDY OF SINGLE-PATIENT IMAGING AND DOSIMETRY TESTING OF LUTETIUM (177LU) RHPSMA-10.1 AND LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN (PLUVICTO®) IN PATIENTS WITH INCURABLE METASTATIC PROSTATE CANCER.
- Code EudraCT: 2024-515264-31
- Protocol number: BET-PSMA-001
- Promoter: Blue Earth Therapeutics
- Molecule/Drug: Lutetium (177Lu) rhPSMA-10.1
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.